A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy ( (ADHERE)

Brief description of study

Study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Demyelinating Polyneuropathy
Age: Between 18 Years - 99 Years
Gender: All

Male and Female Age 18 or older Diagnosed with probable or definite CIDP

Updated on 09 Mar 2024. Study ID: 834668

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).